[Clofibrate in type IIa hyperlipoproteinemia. Reduction of apolipoprotein B (author's transl)].
After changing over from the usual eating habits to a "reasonable" restricted diet rich in polyene saturated fats and saturated fatty acids, additional treatment with 1 g clofibrate twice daily produces a significant reduction of concentration of total cholesterol and Apo B by about 24% in the serum of patients with Type IIa hyperlipoproteinemia after 2 weeks. In contrast to this the serum concentration of triglycerides and phospholipids shows an insignificant tendency to fall during the whole duration of the trial. The results suggest that the additional cholesterol reducing action of clofibrate in patients with hyperlipoproteinemia Type IIa who have already been treated by diet is mainly achieved by the reduction of LDL-cholesterol, the atherogenic properties of which are well known.
D000328:Adult; D000368:Aged; D001053:Apolipoproteins / Q000097:blood*; D002784:Cholesterol / Q000097:blood; D002994:Clofibrate / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006937:Hypercholesterolemia / Q000178:diet therapy / Q000188:drug therapy*; D008077:Lipoproteins, LDL / Q000097:blood; D008297:Male; D008875:Middle Aged; D010743:Phospholipids / Q000097:blood; D014280:Triglycerides / Q000097:blood
D001053:Apolipoproteins; D008077:Lipoproteins, LDL; D010743:Phospholipids; D014280:Triglycerides; D002784:Cholesterol; D002994:Clofibrate
Clofibrat bei Hyperlipoproteinämie Typ IIa. Verminderung von Apolipoprotein B.